Niyamba Pharmaceutical Profile
Key Indicators
- Authorised Capital ₹ 1.00 M
- Paid Up Capital ₹ 0.10 M
- Company Age 8 Year, 11 Months
- Last Filing with ROC 31 Mar 2024
- Open Charges ₹ 1.00 M
- Revenue Growth -0.38%
- Profit Growth -80.64%
- Ebitda -76.12%
- Net Worth -3.32%
- Total Assets -9.47%
About Niyamba Pharmaceutical
Niyamba Pharmaceutical Private Limited (NPPL) is a Private Limited Indian Non-Government Company incorporated in India on 17 March 2016 (Eight years and 11 months 8 days old ). Its registered office is in Satna, Madhya Pradesh, India.
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 1.00 M and a paid-up capital of Rs 0.10 M.
The company currently has active open charges totaling ₹1.00 M.
Rahul Singh, Prema Gaharwar, and Arti Soni serve as directors at the Company.
Company Details
- Location
Satna, Madhya Pradesh, India
- Telephone
+91-XXXXXXXXXX
- Email Address
- Website
- Social Media
Corporate Identity Details
- CIN/LLPIN
U24230MP2016PTC035563
- Company No.
035563
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
17 Mar 2016
- Date of AGM
30 Sep 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Gwalior
Industry
What products or services does Niyamba Pharmaceutical Private Limited offer?
Niyamba Pharmaceutical Private Limited offers a wide range of products and services, including Pain Relief Drugs & Pharmaceuticals, Anti Inflammatory Drugs, Nutraceuticals & Dietary Supplements, Nutritional Supplements, Anti Infective Drugs & Medicines, Antiviral Drugs, Vitamin Tablets & Capsules, Multivitamin Syrup & Drops, Common Disease Medicines, Pharmaceutical Medicine.
Who are the key members and board of directors at Niyamba Pharmaceutical?
Board Members (3)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Rahul Singh  | Director | 05-Mar-2022 | Current |
| Prema Gaharwar | Director | 21-Apr-2017 | Current |
| Arti Soni | Director | 21-Apr-2017 | Current |
Financial Performance of Niyamba Pharmaceutical.
Niyamba Pharmaceutical Private Limited, for the financial year ended 2023, experienced Minor drop in revenue, with a 0.38% decrease. The company also saw a substantial fall in profitability, with a 80.64% decrease in profit. The company's net worth dipped by a decrease of 3.32%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Niyamba Pharmaceutical?
In 2023, Niyamba Pharmaceutical had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Anant Webtech Private LimitedArti Soni is a mutual person
- Aks It Universe Private Limited
Arti Soni is a mutual person
Charges (Loans)
₹1.00 M
₹0
Charges Breakdown by Lending Institutions
- Others : 0.10 Cr
Latest Charge Details
| Date | Lender | Amount | Status |
|---|---|---|---|
| 12 Dec 2019 | Others | ₹1.00 M | Open |
How Many Employees Work at Niyamba Pharmaceutical?
Unlock and access historical data on people associated with Niyamba Pharmaceutical, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Niyamba Pharmaceutical, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Niyamba Pharmaceutical's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
